Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype‐guided doses in renal …
S Anutrakulchai, C Pongskul… - British Journal of …, 2019 - Wiley Online Library
Aims Although cytochromeP450 (CYP) 3A5 gene polymorphism affects personalized
tacrolimus doses, there is no consensus as to whether CYP3A5 genotypes should be …
tacrolimus doses, there is no consensus as to whether CYP3A5 genotypes should be …
Clinical impact of the adaptation of initial tacrolimus dosing to the CYP3A5 genotype after kidney transplantation: systematic review and meta-analysis of randomized …
H Yang, Y Sun, X Yu, X Hu, W Wang, X Zhang… - Clinical …, 2021 - Springer
Objective The aim of this systematic review and meta-analysis was to compare the clinical
outcomes between genotype-guided and conventional tacrolimus doses in kidney …
outcomes between genotype-guided and conventional tacrolimus doses in kidney …
Comparison of tacrolimus starting doses based on CYP3A5 phenotype or genotype in kidney transplant recipients
B Largeau, CBL Guellec, H Longuet… - Progress in …, 2019 - journals.sagepub.com
Background: Selection of expected phenotypes (ie, expressers/non-expressers) is currently
used in CYP3A5* 3 genotype-based tacrolimus dosing. The authors assessed whether a …
used in CYP3A5* 3 genotype-based tacrolimus dosing. The authors assessed whether a …
Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus
H Bruckmueller, AN Werk, L Renders… - Therapeutic drug …, 2015 - journals.lww.com
Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …
Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study
M De Meyer, V Haufroid, N Kanaan, T Darius… - …, 2016 - Taylor & Francis
Aim: The once daily tacrolimus formulation (Tac-OD) has been associated with better patient
adherence and low variability in exposure. Patients carrying the CYP3A5* 1 allele show …
adherence and low variability in exposure. Patients carrying the CYP3A5* 1 allele show …
[HTML][HTML] A randomized controlled trial comparing the efficacy of Cyp3a5 genotype‐based with body‐weight‐based tacrolimus dosing after living donor kidney …
N Shuker, R Bouamar, RHN van Schaik… - American Journal of …, 2016 - Elsevier
Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose
to achieve therapeutic exposure compared with nonexpressers. This randomized‐controlled …
to achieve therapeutic exposure compared with nonexpressers. This randomized‐controlled …
Impact of CYP3A4* 22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines
L Elens, A Capron, RHN van Schaik… - Therapeutic drug …, 2013 - journals.lww.com
Background: Tacrolimus (Tac) metabolism is mainly mediated by the cytochrome P450 3A
(CYP3A) subfamily. Recently, it has been reported that kidney transplant recipients carrying …
(CYP3A) subfamily. Recently, it has been reported that kidney transplant recipients carrying …
The pharmacogenetics of tacrolimus and its implications for personalized therapy in kidney transplant recipients
MI Francke, BCM de Winter, L Elens… - Expert Review of …, 2020 - Taylor & Francis
Twenty-five years after its approval by the FDA and EMA, tacrolimus remains the
cornerstone of immunosuppressive treatment following solid organ transplantation [1, 2] …
cornerstone of immunosuppressive treatment following solid organ transplantation [1, 2] …
[HTML][HTML] Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach
PF Katsakiori, EP Papapetrou… - … journal of medical …, 2010 - ncbi.nlm.nih.gov
Background: The aim of our study was to determine the impact of CYP3A5* 1 and CYP3A5*
3 on the kinetics of tacrolimus in renal transplant recipients. Material and methods: Forty …
3 on the kinetics of tacrolimus in renal transplant recipients. Material and methods: Forty …
Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation
S Vannaprasaht, S Reungjui, D Supanya… - Clinical …, 2013 - Elsevier
Abstract Background Cytochrome P450 (CYP) 3A4 and 3A5 are major isoforms involved in
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …
相关搜索
- cyp3a5 genotype kidney transplantation
- cyp3a5 genotype tacrolimus dosing
- tacrolimus doses concentration achievement
- transplantation patients concentration achievement
- transplantation patients tacrolimus doses
- allograft survival concentration achievement
- allograft survival transplantation patients
- renal transplantation tacrolimus pharmacokinetics
- allograft survival tacrolimus doses
- cyp3a5 genotype clinical impact
- tacrolimus dosing kidney transplantation
- cyp3a5 phenotype comparison of tacrolimus
- renal transplantation early period
- cyp3a5 genotype body weight
- cyp3a5 genotype meta analysis
- renal transplantation impact of cyp3a4